RxDoctor Payments DataLook up a doctor →

Ramprasad Dandillaya, MD

Cardiovascular Disease · Las Vegas, NVNPI 1316900236

Payments from drug & device makers

$1,784,970in general payments, 2019–2025

Across 751 payments — averaging $2376.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$780K
  • GSK$584K
  • Janssen Research & Development, LLC$124K
  • Amgen$106K
  • Sanofi$69K
  • Novartis$41K
  • plus $81K from 54 others
$1,666in research payments, 2019–2025

Across 9 payments — averaging $185.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Regeneron24$780,102
GSK171$583,916
Janssen Research & Development, LLC27$123,959
Amgen(2 entities)88$106,204
Sanofi13$68,650
Novartis96$40,938
AstraZeneca21$33,745
Bayer26$17,880
Axsome Therapeutics, Inc.1$15,353
Boehringer Ingelheim Pharma GmbH & Co.kg1$6,677
Edwards Lifesciences21$749
E.r. Squibb & Sons, L.L.C.32$576
Boehringer Ingelheim24$556
Pfizer26$549
Boehringer Ingelheim International GmbH3$431
Boston Scientific7$420
Novo Nordisk17$392
Johnson & Johnson12$366
Alnylam Pharmaceuticals Inc.16$359
Abbott6$267
Heartflow, Inc.11$212
Angiodynamics, Inc.1$197
Mylan Specialty L.p.7$186
Lilly USA, LLC8$157
Biosense Webster, Inc.1$125
Mallinckrodt Hospital Products Inc.4$119
Verona Pharma, Inc.4$111
BD1$91
Esperion Therapeutics, Inc.5$85
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)5$81
Kiniksa Pharmaceuticals International, PLC3$72
Arbor Pharmaceuticals, Inc.4$72
Amarin Pharma, Inc.3$71
Merck3$70
Regeneron Healthcare Solutions, Inc.3$65
Exact Sciences3$63
Shionogi Inc2$62
Kestra Medical Technology Services, Inc.2$59
AbbVie(2 entities)3$58
Lexicon Pharmaceuticals, Inc.3$58
Travere Therapeutics, Inc.2$55
Astellas Pharma US Inc3$53
Otsuka America Pharmaceutical, Inc.2$49
Azurity Pharmaceuticals, Inc.3$48
Kiniksa Pharmaceuticals, Ltd.2$45
Antares Pharma, Inc.2$43
Pulmonx Corporation2$42
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$39
Electromed, Inc.2$36
Idorsia Pharmaceuticals US Inc2$33
Viatris Specialty LLC1$32
Viiv Healthcare Company1$31
Gilead1$30
Preventice Services, LLC2$30
Dexcom, Inc.1$26
Irhythm Technologies, Inc.1$25
Bardy Diagnostics, Inc.1$23
GRT US Holding, Inc.1$23
Sanofi-aventis U.S. LLC1$23
Actelion Pharmaceuticals US, Inc.1$21

How this compares

$1,784,970 in reported general payments places this provider in the 95th percentile of 165 cardiovascular disease providers in Nevada.

See all cardiovascular disease providers in Nevada →

Medicare billing

Part B allowed, 2024
$997,884
Medicare patients
954
Services billed
25,825

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Las Vegas

See the full list for Nevada →

Where these figures come from

Is this you, or does something look wrong? →